Galena and NCI to start Phase II trial NeuVax to treat ductal carcinoma in Situ patients
US-based biopharmaceutical firm Galena Biopharma has entered into a collaboration with the National Cancer Institute (NCI) to start a new, Phase II clinical trial with NeuVax (nelipepimut-S) in patients diagnosed with ductal carcinoma in situ (DCIS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Clinical Trials | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Pharmaceuticals